Company: SCLXW
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0000950170-25-071904
Chunk: 42

Company: Scilex Holding Co
Filing Date: 2025-05-15
Form: 424B3
Chunk 42
---
anche B Noteholders agreed to defer the Company’s obligation to make the First Amortization Payment until January 31, 2025 and then further to October 8, 2026. In consideration of such deferral, (i) SCLX JV delivered to the Tranche B Noteholders an aggregate of 142,855 shares of Common Stock held by SCLX JV, with a fair value of $2.2 million on the date of delivery, which was recorded as financing costs within the selling, general and administrative expenses in the Company’sunaudited condensedconsolidated statements of operations, (ii) the Company paid an aggregate of $1.1 million in respect of a portion of the First Amortization Payment and related make-whole interest, and (iii) the Company entered into the Gloperba-Elyxyb Royalty Purchase Agreement (as described below).

The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche B Notes (in thousands):

<div align='center'>22</div>

|                                                     | March 31, 
 2025      |        |   |
|:----------------------------------------------------|:----------|-------:|:--|
| Ending Balance as of December 31, 2024              | $         | 23,560 |   |
| Repayment of Tranche B Notes principal and interest |           | (1,596 | ) |
| Change in fair value of Tranche B Notes             |           |  2,516 |   |
| Ending Balance as of March 31, 2025                 | $         | 24,480 |   |

Aggregate principal repayments for the Company’s outstanding debt will be $46.3 million and $19.3 million in 2025 and 2026, respectively. ZTlido Royalty Purchase Agreement On October 8, 2024, in connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, the Company and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Purchasers. Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido Royalty Purchasers the right to receive 8% of all aggregate net sales worldwide (the “ZTlido Purchased Receivables”) with respect to ZTlido, SP-103 and any related, improved, successor, replacement